Undisclosed GABAB PAM / Addex - LARVOL DELTA

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update (GlobeNewswire) - "Positive data from this program in multiple preclinical models was recently presented at the prestigious American cough conference. We have also regained rights to our Phase 2 mGlu2 PAM asset, ADX71149...R&D expenses decreased by CHF 0.1 million during three-month period ended March 31, 2025 compared to the same period ended March 31, 2024 primarily due to lower GABAB PAM outsourced R&D expenses as we successfully completed the research phase of our agreement with Indivior on June 30, 2024."

Commercial • Chronic Cough • CNS Disorders

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference (GlobeNewswire) - "A presentation given by Mikhail Kalinichev, Head of Translational Science at Addex will describe the progress seen to date with the Addex GABAB PAM cough program, including antitussive data from in vivo models. Addex lead drug candidate is ready to start IND enabling studies."

Preclinical • Cough

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) (GlobeNewswire) - "Addex Therapeutics...announced today that positive results from the Company’s novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13th LICS) on July 19 and an abstract is available to conference participants on-line from today....'To our knowledge, this is the first time a highly selective GABAB PAM has demonstrated antitussive activity in animal models of cough,'....'We believe that a GABAB PAM with antitussive efficacy, combined with reduced centrally-mediated side-effects and improved tolerability in comparison to baclofen, has the potential to become a best-in-class treatment for chronic cough.'"

Preclinical • Chronic Cough

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) - "Addex Therapeutics...today reported its half-year and second quarter financial results for the periods ended June 30, 2023 and provided a corporate update...GABAB PAM Indivior strategic partnership for substance use disorders extended through to end June 2024 with CHF2.7 million of committed research funding - multiple drug candidates in clinical candidate selection phase...R&D expenses decreased by CHF 5.9 million to CHF 3.6 million in the first half of 2023 compared to CHF 9.5 million in the first half of 2022 and by CHF 3.9 million to CHF 1.8 million in the second quarter of 2023 compared to CHF 5.7 million in the second quarter of 2022. The decrease in R&D expenses is primarily due to decreased dipraglurant related external research and development activities."

Commercial • Licensing / partnership • Chronic Cough • CNS Disorders • Cough • Pain • Parkinson's Disease • Respiratory Diseases

Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration (GlobeNewswire) - "Addex Therapeutics...today announced that its collaboration agreement with Indivior PLC (LON: INDV) for the discovery of novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates for the treatment of substance use disorder has been extended until June 30, 2024. As part of the extended agreement, Indivior has committed CHF 2.7 million to support research and discovery activities during this period. Addex retains exclusive rights to advance its own independent GABAB PAM program and is developing compounds for the treatment of chronic cough."

Licensing / partnership • Chronic Cough • Cough • Respiratory Diseases